A Study to Evaluate the Use of Resmetirom in Participants With MASLD and HIV

Summary

The purpose of this research study is to test the safety and effectiveness of the study drug, resmetirom, in participants with MASLD and HIV. This is a research study to test a drug that is already on the market with a population that was not included in the original clinical trials. Participants will be people over age 18 with HIV who are on antiretroviral therapy and have been diagnosed with MASLD. Researchers will compare resmetirom to placebo (a look-alike substance that contains no drug) to see if resmetirom decreases the amount of fat in the liver.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

• MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease
• HIV (Human Immunodeficiency Virus)

Eligibility basics and study details

Study type

Interventional

Phase

Phase 2

Ages

18 years and older

Sex

All

Healthy volunteers

Not accepted

Sponsor

Naga P. Chalasani

Last updated on ClinicalTrials.gov

July 30, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites